miCure Therapeutics is developing microRNA therapeutics and diagnostics for CNS disorders based on inventions by Prof. Alon Chen of the Department of Neurobiology and Dr. Eran Hornstein of the Department of Molecular Genetics at The Weizmann Institute of Science. Currently, miCure Therapeutics is focused on Neurodegenerative diseases such as ALS, and neuropsychiatric diseases (mood disorders).
Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS) is a motor neuron disease that is characterized by muscle weakness and atrophy due to progressive degeneration of lower and upper motor neurons. ALS is a devastating disease that rapidly progresses and lacks effective therapy. There is, therefore, a great need for new and novel therapeutic modalities to treat ALS. miCure Therapeutics acknowledges patients' need and seeks to develop a microRNA based therapy for ALS.
Mood disorders are a group of high prevalence indications with significant morbidity and potential mortality. The two main subtypes of mood disorder are unipolar (depressive episodes only) and bipolar disorder (mania or hypomania, with depressive episodes). Treatments include medication, psychotherapy, or a combination of the two. With proper treatment, most patients can lead productive lives. However, many patients require second and third line treatments with some presenting severe symptoms even after treatment, being resistant or non-responsive to conventional treatments. miCure Therapeutics develops microRNA-based therapeutics and diagnostics for Major Depression.
Visit www.micurerx.com for more information